Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
Significant corporate and scientific progress in 2023 Innovations to End-to-End Platform technologies and IP portfolio Pipeline additions with multiple KRAS neoantigen targets Advancement of lead program MDG1015 with IND/CTA approval expected in 2H …